Pulmonx (LUNG) Financials

Pulmonx logo
$2.73 -0.07 (-2.50%)
Closing price 04:00 PM Eastern
Extended Trading
$2.73 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Pulmonx

Annual Income Statements for Pulmonx

This table shows Pulmonx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
-18 -21 -32 -49 -59 -61 -56
Consolidated Net Income / (Loss)
-18 -21 -32 -49 -59 -61 -56
Net Income / (Loss) Continuing Operations
-18 -21 -32 -49 -59 -61 -56
Total Pre-Tax Income
-18 -20 -32 -48 -59 -60 -56
Total Operating Income
-15 -18 -32 -47 -59 -62 -58
Total Gross Profit
12 22 21 36 40 51 62
Total Revenue
20 33 33 48 54 69 84
Operating Revenue
20 33 - 48 54 69 84
Total Cost of Revenue
7.72 10 12 13 14 18 22
Operating Cost of Revenue
7.72 10 - 13 14 18 22
Total Operating Expenses
27 40 54 83 99 113 120
Selling, General & Admin Expense
20 34 46 70 83 95 102
Research & Development Expense
6.99 6.05 7.46 13 15 18 18
Total Other Income / (Expense), net
-3.42 -2.50 0.31 -1.01 0.07 1.66 1.81
Interest Expense
2.52 2.32 3.18 0.83 1.07 3.23 3.51
Interest & Investment Income
0.02 0.43 0.21 0.40 1.53 5.57 5.06
Other Income / (Expense), net
-0.92 -0.62 3.28 -0.59 -0.40 -0.67 0.26
Income Tax Expense
0.01 0.36 0.21 0.34 0.35 0.57 0.50
Basic Earnings per Share
($11.03) ($11.66) ($3.16) ($1.35) ($1.59) ($1.60) ($1.44)
Weighted Average Basic Shares Outstanding
1.67M 1.78M 10.18M 36.13M 37.10M 37.97M 39.11M
Diluted Earnings per Share
($11.03) ($11.66) ($3.16) ($1.35) ($1.59) ($1.60) ($1.44)
Weighted Average Diluted Shares Outstanding
1.67M 1.78M 10.18M 36.13M 37.10M 37.97M 39.11M
Weighted Average Basic & Diluted Shares Outstanding
1.67M 1.78M 10.18M 37.02M 37.65M 38.54M 39.80M

Quarterly Income Statements for Pulmonx

This table shows Pulmonx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-14 -14 -15 -14 -13 -14 -15 -14 -14 -10 -8.39
Consolidated Net Income / (Loss)
-14 -14 -15 -14 -13 -14 -15 -14 -14 -10 -8.39
Net Income / (Loss) Continuing Operations
-14 -14 -15 -14 -13 -14 -15 -14 -14 -10 -8.39
Total Pre-Tax Income
-14 -14 -15 -14 -13 -14 -15 -14 -14 -9.95 -8.24
Total Operating Income
-14 -15 -16 -14 -13 -15 -15 -14 -13 -9.06 -7.49
Total Gross Profit
14 14 15 15 18 16 17 16 16 18 17
Total Revenue
19 19 21 20 24 23 24 22 21 23 23
Operating Revenue
19 19 21 20 24 23 24 22 21 23 23
Total Cost of Revenue
4.88 4.78 5.48 5.36 6.18 6.20 6.66 5.45 4.54 5.01 5.44
Operating Cost of Revenue
4.88 4.78 5.48 5.36 6.18 6.20 6.66 5.45 4.54 5.01 5.44
Total Operating Expenses
28 29 31 29 31 31 32 30 29 27 25
Selling, General & Admin Expense
24 24 25 25 27 26 27 26 24 22 20
Research & Development Expense
3.90 4.21 5.62 3.74 4.00 4.76 5.31 4.85 4.90 5.03 4.86
Total Other Income / (Expense), net
0.28 0.97 0.38 0.18 0.28 0.25 -0.19 0.56 -0.55 -0.89 -0.75
Interest Expense
0.90 0.88 0.89 0.89 0.84 0.78 0.80 0.81 0.98 1.22 1.23
Interest & Investment Income
1.54 1.44 1.31 1.27 1.05 0.86 0.72 0.61 0.35 0.33 0.35
Other Income / (Expense), net
-0.36 0.42 -0.04 -0.20 0.08 0.17 -0.12 0.76 0.08 -0.00 0.14
Income Tax Expense
0.25 0.19 0.08 0.19 0.04 0.14 0.18 0.13 0.15 0.13 0.15
Basic Earnings per Share
($0.36) ($0.36) ($0.39) ($0.36) ($0.33) ($0.36) ($0.38) ($0.34) ($0.33) ($0.24) ($0.19)
Weighted Average Basic Shares Outstanding
37.97M 38.64M 38.94M 39.28M 39.11M 39.95M 40.43M 40.94M 41.90M 42.47M 43.18M
Diluted Earnings per Share
($0.36) ($0.36) ($0.39) ($0.36) ($0.33) ($0.36) ($0.38) ($0.34) ($0.33) ($0.24) ($0.19)
Weighted Average Diluted Shares Outstanding
37.97M 38.64M 38.94M 39.28M 39.11M 39.95M 40.43M 40.94M 41.90M 42.47M 43.18M
Weighted Average Basic & Diluted Shares Outstanding
38.54M 38.82M 39.15M 39.49M 39.80M 40.26M 40.75M 41.25M 42.24M 42.95M 43.55M

Annual Cash Flow Statements for Pulmonx

This table details how cash moves in and out of Pulmonx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
-6.08 11 217 -83 -47 -18 -13
Net Cash From Operating Activities
-18 -21 -31 -41 -45 -38 -32
Net Cash From Continuing Operating Activities
-18 -21 -31 -41 -45 -38 -32
Net Income / (Loss) Continuing Operations
-18 -21 -32 -49 -59 -61 -56
Consolidated Net Income / (Loss)
-18 -21 -32 -49 -59 -61 -56
Depreciation Expense
0.27 0.37 0.48 0.87 1.51 1.55 1.49
Amortization Expense
0.04 -0.03 2.40 0.17 -0.15 -0.98 -1.56
Non-Cash Adjustments To Reconcile Net Income
1.30 1.32 2.63 14 19 25 27
Changes in Operating Assets and Liabilities, net
-1.52 -1.71 -3.91 -7.85 -7.01 -2.56 -1.70
Net Cash From Investing Activities
0.20 -14 13 -46 -4.23 -2.01 17
Net Cash From Continuing Investing Activities
0.20 -14 13 -46 -4.23 -2.01 17
Purchase of Property, Plant & Equipment
-0.32 -0.72 -0.91 -3.67 -1.32 -0.81 -1.45
Purchase of Investments
0.00 -21 0.00 -53 -47 -46 -28
Sale and/or Maturity of Investments
0.50 7.94 14 10 44 45 47
Net Cash From Financing Activities
12 46 235 4.46 2.42 21 1.36
Net Cash From Continuing Financing Activities
12 46 235 4.46 2.42 21 1.36
Repayment of Debt
0.00 0.00 -20 -0.04 -0.14 -0.09 -0.10
Issuance of Debt
12 6.00 53 - 0.00 20 0.00
Issuance of Common Equity
0.00 0.00 201 2.65 1.94 1.18 1.24
Other Financing Activities, net
0.11 0.53 3.09 1.87 0.64 0.31 0.22
Effect of Exchange Rate Changes
- - 0.13 0.11 0.15 0.03 0.08
Cash Interest Paid
1.36 1.40 3.06 0.72 0.85 2.98 3.48
Cash Income Taxes Paid
0.23 0.20 0.26 0.32 0.40 0.47 0.56

Quarterly Cash Flow Statements for Pulmonx

This table details how cash moves in and out of Pulmonx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-11 -13 -6.67 -0.15 7.59 3.65 0.91 1.09 -8.18 -5.73 -3.16
Net Cash From Operating Activities
-8.45 -12 -5.77 -7.24 -6.73 -13 -3.91 -8.16 -10 -5.21 -3.18
Net Cash From Continuing Operating Activities
-8.45 -12 -5.77 -7.24 -6.73 -13 -3.91 -8.16 -10 -5.21 -3.18
Net Income / (Loss) Continuing Operations
-14 -14 -15 -14 -13 -14 -15 -14 -14 -10 -8.39
Consolidated Net Income / (Loss)
-14 -14 -15 -14 -13 -14 -15 -14 -14 -10 -8.39
Depreciation Expense
0.29 0.42 0.40 0.38 0.29 0.28 0.30 0.25 0.22 0.22 0.22
Amortization Expense
-0.31 -0.38 -0.46 -0.39 -0.33 -0.20 -0.12 -0.03 0.05 0.13 0.13
Non-Cash Adjustments To Reconcile Net Income
5.89 6.54 8.31 6.10 5.69 5.93 6.42 5.70 4.87 4.26 4.41
Changes in Operating Assets and Liabilities, net
-0.42 -4.63 1.31 0.83 0.79 -4.78 4.67 -0.13 -1.58 0.26 0.47
Net Cash From Investing Activities
-2.76 -2.51 -0.84 6.75 14 16 5.47 8.71 -0.01 -0.00 -0.01
Net Cash From Continuing Investing Activities
-2.76 -2.51 -0.84 6.75 14 16 5.47 8.71 -0.01 -0.00 -0.01
Purchase of Property, Plant & Equipment
-0.20 -0.45 -0.47 -0.42 -0.11 -0.30 -0.05 -0.09 -0.01 -0.00 -0.01
Net Cash From Financing Activities
0.02 0.86 -0.02 0.46 0.06 0.66 -0.07 0.18 2.03 -0.51 0.16
Net Cash From Continuing Financing Activities
0.02 0.86 -0.02 0.46 0.06 0.66 -0.07 0.18 2.03 -0.51 0.16
Repayment of Debt
-0.05 - - - -0.05 0.00 - -0.02 -37 -0.51 -0.05
Issuance of Common Equity
- 0.81 - 0.43 0.00 0.55 - 0.20 0.20 - 0.20
Other Financing Activities, net
0.06 0.06 0.02 0.03 0.11 0.11 0.03 0.01 0.04 - 0.01
Effect of Exchange Rate Changes
-0.21 0.05 -0.05 -0.12 0.19 -0.11 -0.58 0.36 -0.10 0.00 -0.13
Cash Interest Paid
0.88 0.88 0.90 0.88 0.82 0.79 0.78 0.79 0.79 1.11 0.90
Cash Income Taxes Paid
0.10 0.17 0.11 0.19 0.10 0.11 0.11 0.15 0.08 0.21 0.21

Annual Balance Sheets for Pulmonx

This table presents Pulmonx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
54 264 235 194 178 163 129
Total Current Assets
41 250 208 169 150 136 102
Cash & Equivalents
15 232 148 102 84 71 70
Restricted Cash
0.00 0.23 0.23 0.23 0.24 0.26 0.26
Accounts Receivable
5.51 4.23 6.56 8.68 12 13 12
Inventories, net
5.61 11 16 15 17 17 16
Prepaid Expenses
1.60 3.23 4.88 4.34 4.24 4.47 3.76
Plant, Property, & Equipment, net
0.90 1.47 4.81 4.69 4.03 2.91 2.22
Total Noncurrent Assets
12 12 22 20 23 24 25
Goodwill
2.33 2.33 2.33 2.33 2.33 2.33 2.33
Other Noncurrent Operating Assets
8.70 9.51 8.81 12 6.58 21 23
Total Liabilities & Shareholders' Equity
54 264 235 194 178 163 129
Total Liabilities
36 38 42 40 59 77 75
Total Current Liabilities
14 13 18 18 23 24 20
Short-Term Debt
- - 0.09 0.09 2.16 3.18 0.11
Accounts Payable
2.68 1.47 1.58 1.76 1.50 3.83 3.91
Accrued Expenses
9.46 8.65 13 13 16 16 15
Current Deferred Revenue
0.17 0.07 0.16 0.12 0.10 0.14 0.02
Current Deferred & Payable Income Tax Liabilities
0.23 0.09 0.15 0.02 0.09 0.05 0.26
Other Current Liabilities
1.61 2.24 2.20 3.23 3.07 0.78 1.21
Total Noncurrent Liabilities
21 25 24 21 36 53 55
Long-Term Debt
15 17 18 17 35 34 37
Noncurrent Deferred & Payable Income Tax Liabilities
0.04 0.06 0.04 0.09 0.11 0.09 0.07
Other Noncurrent Operating Liabilities
6.40 7.62 6.84 3.85 1.11 19 18
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-187 226 193 154 118 86 54
Total Preferred & Common Equity
-187 226 193 154 118 86 54
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-187 226 193 154 118 86 54
Common Stock
22 467 483 503 527 551 573
Retained Earnings
-211 -243 -291 -350 -411 -468 -522
Accumulated Other Comprehensive Income / (Loss)
1.37 1.69 1.71 1.58 2.64 2.11 2.36

Quarterly Balance Sheets for Pulmonx

This table presents Pulmonx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
193 185 165 173 167 151 147 138 120 115 110
Total Current Assets
164 147 148 146 141 124 120 111 93 88 84
Cash & Equivalents
102 95 70 63 63 75 75 77 62 56 53
Restricted Cash
0.47 0.24 0.24 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26
Accounts Receivable
8.94 10 11 11 12 14 16 14 11 12 12
Inventories, net
16 16 17 17 17 17 16 16 16 16 15
Prepaid Expenses
4.23 4.42 3.82 3.30 4.26 4.20 3.46 4.38 3.78 3.39 3.66
Plant, Property, & Equipment, net
4.22 4.07 4.22 2.83 2.98 2.83 2.66 2.44 2.06 1.89 1.76
Total Noncurrent Assets
24 34 12 24 23 24 25 25 25 25 24
Goodwill
2.33 2.33 2.33 2.33 2.33 2.33 2.33 2.33 2.33 2.33 2.33
Other Noncurrent Operating Assets
9.59 7.92 5.80 21 21 22 22 22 23 22 22
Total Liabilities & Shareholders' Equity
193 185 165 173 167 151 147 138 120 115 110
Total Liabilities
59 59 54 71 73 73 78 78 74 76 76
Total Current Liabilities
20 20 21 16 18 25 22 23 19 20 21
Short-Term Debt
0.09 0.09 5.23 0.09 0.10 7.80 0.10 0.11 0.10 0.10 0.10
Accounts Payable
2.38 3.19 3.13 3.18 4.58 4.28 6.56 6.42 3.47 4.68 4.51
Accrued Expenses
14 14 10 12 13 12 14 15 14 14 15
Current Deferred Revenue
0.10 0.09 0.11 0.11 0.11 0.13 0.08 0.09 0.03 0.02 0.01
Current Deferred & Payable Income Tax Liabilities
0.04 0.00 0.07 0.07 0.07 0.09 0.21 0.19 0.33 0.26 0.17
Other Current Liabilities
3.35 3.44 2.69 1.07 0.66 1.10 1.12 1.14 1.24 1.28 1.39
Total Noncurrent Liabilities
40 39 33 55 55 48 56 55 55 55 55
Long-Term Debt
37 37 32 37 37 29 37 37 37 37 38
Noncurrent Deferred & Payable Income Tax Liabilities
0.09 0.10 0.14 0.12 0.13 0.08 0.04 0.05 0.07 0.06 0.07
Other Noncurrent Operating Liabilities
2.40 1.54 0.65 18 18 19 19 18 18 18 17
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
134 126 110 101 94 78 69 60 46 39 34
Total Preferred & Common Equity
134 126 110 101 94 78 69 60 46 39 34
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
134 126 110 101 94 78 69 60 46 39 34
Common Stock
514 521 533 539 546 557 564 569 579 582 586
Retained Earnings
-382 -397 -425 -440 -454 -482 -497 -511 -535 -545 -554
Accumulated Other Comprehensive Income / (Loss)
1.96 1.94 1.96 1.97 2.53 2.20 2.64 2.24 2.17 2.05 1.72

Annual Metrics And Ratios for Pulmonx

This table displays calculated financial ratios and metrics derived from Pulmonx's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics
- - - - - - -
Revenue Growth
0.00% 62.94% 0.42% 47.91% 10.84% 27.98% 22.01%
EBITDA Growth
0.00% -15.71% -44.39% -79.07% -23.07% -7.58% 7.28%
EBIT Growth
0.00% -15.57% -57.41% -64.85% -23.27% -6.06% 8.24%
NOPAT Growth
0.00% -18.51% -81.25% -46.31% -23.96% -5.62% 6.83%
Net Income Growth
0.00% -12.04% -55.68% -50.98% -21.09% -3.26% 7.31%
EPS Growth
0.00% -5.71% 72.90% 57.28% -17.78% -0.63% 10.00%
Operating Cash Flow Growth
0.00% -12.89% -47.52% -35.11% -8.93% 16.58% 16.15%
Free Cash Flow Firm Growth
0.00% 0.00% -74.41% -37.83% -10.83% 5.10% 12.37%
Invested Capital Growth
0.00% 0.00% 155.73% 67.55% 22.52% -0.87% -10.84%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 8.71% 3.31% 5.94% 5.66%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -11.61% -3.30% -0.20% 1.59%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -8.19% -2.92% 0.24% 1.60%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -6.80% -4.01% 1.13% 0.86%
Net Income Q/Q Growth
0.00% 0.00% 0.00% -8.25% -2.22% 0.65% 1.25%
EPS Q/Q Growth
0.00% 0.00% 0.00% -118.93% -1.27% 1.23% 2.04%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -14.12% -9.09% 1.97% 3.48% 5.17%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.47% -0.08% 7.49%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 11.99% 1.28% 3.61% -8.11%
Profitability Metrics
- - - - - - -
Gross Margin
61.42% 68.77% 64.77% 73.59% 74.29% 73.90% 74.00%
EBITDA Margin
-78.29% -55.60% -79.94% -96.78% -107.47% -90.33% -68.65%
Operating Margin
-75.25% -54.73% -98.77% -97.70% -109.27% -90.19% -68.87%
EBIT Margin
-79.82% -56.62% -88.75% -98.91% -110.01% -91.17% -68.56%
Profit (Net Income) Margin
-92.38% -63.52% -98.47% -100.51% -109.80% -88.60% -67.30%
Tax Burden Percent
100.07% 101.78% 100.67% 100.71% 100.60% 100.95% 100.89%
Interest Burden Percent
115.65% 110.21% 110.22% 100.90% 99.22% 96.27% 97.29%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -545.39% -277.89% -211.38% -188.03% -181.14% -179.21%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -422.59% -269.46% -203.37% -176.26% -165.56% -159.09%
Return on Net Nonoperating Assets (RNNOA)
0.00% 314.85% 251.48% 188.17% 154.10% 136.46% 123.96%
Return on Equity (ROE)
0.00% -230.53% -26.41% -23.21% -33.94% -44.68% -55.25%
Cash Return on Invested Capital (CROIC)
0.00% -745.39% -365.44% -261.88% -208.27% -180.27% -167.76%
Operating Return on Assets (OROA)
0.00% -34.47% -18.31% -19.20% -27.53% -33.71% -33.73%
Return on Assets (ROA)
0.00% -38.67% -20.32% -19.51% -27.48% -32.76% -33.11%
Return on Common Equity (ROCE)
0.00% 2,405.03% -4.19% -23.21% -33.94% -44.68% -55.25%
Return on Equity Simple (ROE_SIMPLE)
0.00% 11.05% -14.25% -25.18% -38.26% -51.42% -65.72%
Net Operating Profit after Tax (NOPAT)
-11 -12 -23 -33 -41 -43 -40
NOPAT Margin
-52.67% -38.31% -69.14% -68.39% -76.49% -63.13% -48.21%
Net Nonoperating Expense Percent (NNEP)
0.00% -122.80% -8.43% -8.01% -11.78% -15.58% -20.12%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -27.87% -32.84%
Cost of Revenue to Revenue
38.58% 31.23% 35.23% 26.41% 25.71% 26.10% 26.00%
SG&A Expenses to Revenue
101.71% 104.93% 140.76% 144.31% 154.87% 137.76% 121.90%
R&D to Revenue
34.95% 18.56% 22.79% 26.98% 28.69% 26.33% 20.97%
Operating Expenses to Revenue
136.66% 123.49% 163.55% 171.29% 183.56% 164.09% 142.86%
Earnings before Interest and Taxes (EBIT)
-16 -18 -29 -48 -59 -63 -57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-16 -18 -26 -47 -58 -62 -58
Valuation Ratios
- - - - - - -
Price to Book Value (P/BV)
0.00 0.00 10.89 6.11 2.05 4.13 3.12
Price to Tangible Book Value (P/TBV)
0.00 0.00 11.02 6.20 2.08 4.21 3.21
Price to Revenue (P/Rev)
9.50 5.83 75.21 24.40 5.88 7.11 3.20
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 83.41 191.93 51.37 7.71 16.53 9.58
Enterprise Value to Revenue (EV/Rev)
0.00 11.72 68.66 20.82 3.45 5.74 2.43
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - -
Debt to Equity
0.00 0.83 0.08 0.09 0.11 0.31 0.43
Long-Term Debt to Equity
0.00 0.83 0.08 0.09 0.11 0.30 0.40
Financial Leverage
0.00 -0.75 -0.93 -0.93 -0.87 -0.82 -0.78
Leverage Ratio
0.00 2.98 1.30 1.19 1.24 1.36 1.67
Compound Leverage Factor
0.00 3.28 1.43 1.20 1.23 1.31 1.62
Debt to Total Capital
0.00% 45.45% 7.13% 8.35% 10.11% 23.94% 30.23%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.04% 0.05% 1.39% 2.58%
Long-Term Debt to Total Capital
0.00% 45.45% 7.13% 8.30% 10.06% 22.56% 27.65%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 623.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -569.09% 92.87% 91.66% 89.89% 76.06% 69.77%
Debt to EBITDA
0.00 -0.83 -0.66 -0.38 -0.30 -0.60 -0.65
Net Debt to EBITDA
0.00 0.74 8.19 3.71 2.25 1.52 1.12
Long-Term Debt to EBITDA
0.00 -0.83 -0.66 -0.37 -0.30 -0.57 -0.59
Debt to NOPAT
0.00 -1.20 -0.77 -0.53 -0.42 -0.86 -0.92
Net Debt to NOPAT
0.00 1.07 9.47 5.24 3.17 2.18 1.60
Long-Term Debt to NOPAT
0.00 -1.20 -0.77 -0.53 -0.42 -0.81 -0.84
Altman Z-Score
0.00 -2.23 38.86 15.67 2.44 1.77 -1.76
Noncontrolling Interest Sharing Ratio
0.00% 1,143.25% 84.12% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - -
Current Ratio
0.00 2.90 19.96 11.85 9.14 6.50 5.58
Quick Ratio
0.00 2.39 18.82 10.63 8.10 5.58 4.69
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -17 -30 -41 -45 -43 -38
Operating Cash Flow to CapEx
-6,131.33% -2,884.03% -3,362.57% -1,127.43% -3,420.56% -4,660.47% -2,179.47%
Free Cash Flow to Firm to Interest Expense
0.00 -7.37 -9.36 -49.48 -42.65 -13.35 -10.78
Operating Cash Flow to Interest Expense
-7.30 -8.96 -9.63 -49.93 -42.29 -11.64 -8.99
Operating Cash Flow Less CapEx to Interest Expense
-7.42 -9.27 -9.92 -54.35 -43.53 -11.89 -9.41
Efficiency Ratios
- - - - - - -
Asset Turnover
0.00 0.61 0.21 0.19 0.25 0.37 0.49
Accounts Receivable Turnover
0.00 5.91 6.72 8.97 7.04 6.61 6.64
Inventory Turnover
0.00 1.81 1.41 0.95 0.89 1.15 1.29
Fixed Asset Turnover
0.00 36.14 27.55 15.40 11.29 15.75 24.16
Accounts Payable Turnover
0.00 3.80 5.55 8.37 8.26 11.01 8.18
Days Sales Outstanding (DSO)
0.00 61.71 54.30 40.67 51.83 55.23 54.94
Days Inventory Outstanding (DIO)
0.00 201.20 258.82 385.75 408.06 318.78 281.93
Days Payable Outstanding (DPO)
0.00 96.12 65.73 43.59 44.18 33.14 44.59
Cash Conversion Cycle (CCC)
0.00 166.79 247.39 382.83 415.70 340.87 292.27
Capital & Investment Metrics
- - - - - - -
Invested Capital
0.00 4.58 12 20 24 24 21
Invested Capital Turnover
0.00 14.24 4.02 3.09 2.46 2.87 3.72
Increase / (Decrease) in Invested Capital
0.00 4.58 7.13 7.91 4.42 -0.21 -2.58
Enterprise Value (EV)
0.00 382 2,247 1,008 185 394 204
Market Capitalization
190 190 2,462 1,181 315 488 268
Book Value per Share
$0.00 ($105.50) $6.34 $5.25 $4.12 $3.09 $2.17
Tangible Book Value per Share
$0.00 ($107.11) $6.26 $5.17 $4.05 $3.03 $2.11
Total Capital
0.00 33 244 211 171 156 123
Total Debt
0.00 15 17 18 17 37 37
Total Long-Term Debt
0.00 15 17 18 17 35 34
Net Debt
0.00 -13 -214 -174 -130 -94 -65
Capital Expenditures (CapEx)
0.30 0.72 0.91 3.67 1.32 0.81 1.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -1.44 5.67 10 9.18 12 13
Debt-free Net Working Capital (DFNWC)
0.00 27 237 191 151 129 115
Net Working Capital (NWC)
0.00 27 237 190 150 127 112
Net Nonoperating Expense (NNE)
7.94 8.22 9.60 16 18 17 16
Net Nonoperating Obligations (NNO)
0.00 -13 -214 -174 -130 -94 -65
Total Depreciation and Amortization (D&A)
0.31 0.33 2.88 1.03 1.37 0.57 -0.07
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -4.41% 17.33% 21.21% 17.11% 17.59% 15.81%
Debt-free Net Working Capital to Revenue
0.00% 82.56% 725.45% 393.55% 280.55% 188.45% 137.23%
Net Working Capital to Revenue
0.00% 82.56% 725.45% 393.37% 280.39% 185.31% 133.44%
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($3.16) ($1.35) ($1.59) ($1.60) ($1.44)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 35.69M 36.13M 37.10M 37.97M 39.11M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($3.16) ($1.35) ($1.59) ($1.60) ($1.44)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 35.69M 36.13M 37.10M 37.97M 39.11M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($3.16) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 10.18M 37.02M 37.65M 38.54M 39.80M
Normalized Net Operating Profit after Tax (NOPAT)
-11 -12 -23 -33 -41 -43 -40
Normalized NOPAT Margin
-52.67% -38.31% -69.14% -68.39% -76.49% -63.13% -48.21%
Pre Tax Income Margin
-92.32% -62.40% -97.82% -99.80% -109.15% -87.76% -66.71%
Debt Service Ratios
- - - - - - -
EBIT to Interest Expense
-6.34 -7.97 -9.13 -57.77 -55.38 -19.37 -16.38
NOPAT to Interest Expense
-4.18 -5.39 -7.11 -39.94 -38.50 -13.41 -11.52
EBIT Less CapEx to Interest Expense
-6.46 -8.28 -9.42 -62.20 -56.61 -19.62 -16.79
NOPAT Less CapEx to Interest Expense
-4.30 -5.70 -7.40 -44.37 -39.74 -13.66 -11.93
Payout Ratios
- - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -2.80% -7.70% -0.05% -0.05% 0.00% 0.00%

Quarterly Metrics And Ratios for Pulmonx

This table displays calculated financial ratios and metrics derived from Pulmonx's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - 39,796,420.00 40,257,527.00 40,746,556.00 41,247,034.00 42,237,203.00 42,948,269.00
DEI Adjusted Shares Outstanding
- - - - - 39,796,420.00 40,257,527.00 40,746,556.00 41,247,034.00 42,237,203.00 42,948,269.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - -0.36 -0.38 -0.34 -0.33 -0.24 -0.20
Growth Metrics
- - - - - - - - - - -
Revenue Growth
24.98% 29.71% 20.87% 15.39% 23.28% 19.54% 14.80% 5.47% -8.66% -4.62% 6.20%
EBITDA Growth
-0.88% 12.29% 4.22% 6.05% 6.49% -1.69% 6.23% 6.50% 11.88% 40.93% 47.72%
EBIT Growth
1.03% 13.33% 5.69% 7.18% 6.56% -1.95% 4.71% 4.85% 10.54% 39.29% 46.07%
NOPAT Growth
4.83% 11.37% 4.97% 6.90% 3.61% -0.19% 5.24% -1.87% 11.03% 38.82% 47.96%
Net Income Growth
2.77% 13.31% 5.37% 5.07% 5.13% -5.08% 1.00% 1.32% 5.50% 33.57% 39.86%
EPS Growth
5.26% 14.29% 9.30% 7.69% 8.33% 0.00% 2.56% 5.56% 8.33% 36.84% 44.12%
Operating Cash Flow Growth
13.84% 6.71% 26.88% 16.04% 20.35% -12.10% 32.27% -12.70% 23.63% -33.42% 61.00%
Free Cash Flow Firm Growth
34.94% 16.62% 5.51% -1.30% 28.59% 23.19% 25.45% 27.07% 51.14% 38.30% 45.85%
Invested Capital Growth
-0.87% 6.19% 2.01% 0.54% -10.84% -4.31% -7.90% -11.98% -17.99% -5.05% -6.33%
Revenue Q/Q Growth
9.11% -2.20% 10.23% -1.91% 16.57% -5.16% 5.86% -9.88% 0.00% 10.54% 0.35%
EBITDA Q/Q Growth
6.34% 1.59% -11.69% 8.73% 6.78% -7.01% -2.99% 9.00% 0.00% 30.97% 19.46%
EBIT Q/Q Growth
7.52% 1.09% -10.88% 8.48% 6.91% -7.92% -3.64% 8.61% 0.00% 29.67% 18.81%
NOPAT Q/Q Growth
8.28% -4.43% -7.47% 9.56% 5.04% -8.54% -1.65% 2.78% 0.00% 30.09% 17.30%
Net Income Q/Q Growth
6.79% 1.00% -11.47% 7.71% 6.85% -9.66% -5.02% 8.01% 0.00% 26.18% 16.73%
EPS Q/Q Growth
7.69% 0.00% -8.33% 7.69% 8.33% -9.09% -5.56% 10.53% 0.00% 27.27% 20.83%
Operating Cash Flow Q/Q Growth
2.05% -39.60% 51.08% -25.51% 7.07% -96.46% 70.44% -108.85% 0.00% 48.36% 38.95%
Free Cash Flow Firm Q/Q Growth
3.55% -23.24% 2.99% 12.15% 32.01% -32.56% 5.85% 14.06% 0.00% -18.90% 24.58%
Invested Capital Q/Q Growth
3.61% 13.60% -12.88% -1.95% -8.11% 21.91% -16.15% -6.30% 0.00% -2.92% -7.56%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
74.70% 74.67% 73.65% 73.70% 74.02% 72.51% 72.11% 74.65% 77.94% 77.97% 76.19%
EBITDA Margin
-74.19% -74.65% -75.64% -70.38% -56.28% -63.51% -61.78% -62.39% -61.27% -38.26% -30.71%
Operating Margin
-72.21% -77.10% -75.17% -69.30% -56.46% -64.62% -62.05% -66.94% -62.94% -39.80% -32.80%
EBIT Margin
-74.06% -74.90% -75.34% -70.29% -56.13% -63.87% -62.53% -63.41% -62.56% -39.80% -32.20%
Profit (Net Income) Margin
-72.04% -72.92% -73.74% -69.38% -55.44% -64.11% -63.59% -64.91% -66.33% -44.30% -36.76%
Tax Burden Percent
101.82% 101.37% 100.55% 101.38% 100.29% 100.94% 101.18% 100.93% 101.10% 101.34% 101.83%
Interest Burden Percent
95.54% 96.05% 97.35% 97.36% 98.48% 99.42% 100.51% 101.42% 104.86% 109.81% 112.09%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-145.03% -149.89% -172.55% -166.82% -146.92% -149.37% -173.61% -197.58% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-141.34% -146.34% -167.89% -161.92% -142.16% -143.08% -165.91% -190.55% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
116.49% 116.11% 134.55% 127.92% 110.76% 102.80% 121.77% 136.74% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-28.54% -33.78% -38.01% -38.90% -36.15% -46.57% -51.84% -60.84% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)
-180.27% -165.99% -179.61% -177.22% -167.76% -148.16% -167.64% -171.37% 19.76% 5.18% 6.54%
Operating Return on Assets (OROA)
-27.38% -29.89% -31.55% -31.63% -27.62% -35.44% -35.41% -38.03% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-26.64% -29.10% -30.88% -31.22% -27.27% -35.57% -36.01% -38.93% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-28.54% -33.78% -38.01% -38.90% -36.15% -46.57% -51.84% -60.84% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)
0.00% -53.15% -57.19% -60.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.74 -10 -11 -9.89 -9.39 -10 -10 -10 -9.07 -6.34 -5.24
NOPAT Margin
-50.54% -53.97% -52.62% -48.51% -39.52% -45.23% -43.43% -46.86% -44.06% -27.86% -22.96%
Net Nonoperating Expense Percent (NNEP)
-3.69% -3.54% -4.66% -4.90% -4.76% -6.29% -7.70% -7.03% -12.02% -11.34% -11.50%
Return On Investment Capital (ROIC_SIMPLE)
-6.26% - - - -7.64% -8.88% -9.76% -10.37% -10.92% -8.26% -7.28%
Cost of Revenue to Revenue
25.30% 25.33% 26.35% 26.30% 25.98% 27.49% 27.89% 25.35% 22.06% 22.03% 23.81%
SG&A Expenses to Revenue
126.69% 129.44% 121.80% 124.64% 113.64% 116.02% 111.92% 119.05% 117.07% 95.65% 87.69%
R&D to Revenue
20.21% 22.33% 27.02% 18.36% 16.84% 21.10% 22.24% 22.54% 23.80% 22.12% 21.30%
Operating Expenses to Revenue
146.90% 151.77% 148.82% 143.01% 130.47% 137.12% 134.15% 141.59% 140.87% 117.77% 109.00%
Earnings before Interest and Taxes (EBIT)
-14 -14 -16 -14 -13 -14 -15 -14 -13 -9.06 -7.35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-14 -14 -16 -14 -13 -14 -15 -13 -13 -8.71 -7.01
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.13 3.21 2.43 3.46 3.12 3.45 1.51 1.10 1.16 1.40 2.40
Price to Tangible Book Value (P/TBV)
4.21 3.28 2.49 3.54 3.21 3.56 1.56 1.14 1.23 1.49 2.57
Price to Revenue (P/Rev)
7.11 4.87 3.21 4.09 3.20 3.06 1.15 0.72 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
16.53 10.04 7.14 10.97 9.58 8.34 2.62 1.29 1.35 1.76 3.51
Enterprise Value to Revenue (EV/Rev)
5.74 3.72 2.20 3.20 2.43 2.47 0.63 0.29 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.16 33.15 51.94
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.31 0.34 0.37 0.40 0.43 0.48 0.54 0.62 0.82 0.96 1.11
Long-Term Debt to Equity
0.30 0.29 0.37 0.40 0.40 0.38 0.54 0.62 0.81 0.95 1.10
Financial Leverage
-0.82 -0.79 -0.80 -0.79 -0.78 -0.72 -0.73 -0.72 -0.62 -0.61 -0.58
Leverage Ratio
1.36 1.44 1.56 1.60 1.67 1.68 1.88 1.99 2.19 2.42 2.64
Compound Leverage Factor
1.30 1.38 1.51 1.56 1.64 1.67 1.89 2.01 2.30 2.66 2.96
Debt to Total Capital
23.94% 25.20% 26.88% 28.39% 30.23% 32.38% 34.95% 38.21% 44.92% 48.92% 52.51%
Short-Term Debt to Total Capital
1.39% 3.54% 0.07% 0.08% 2.58% 6.79% 0.10% 0.11% 0.13% 0.13% 0.14%
Long-Term Debt to Total Capital
22.56% 21.66% 26.82% 28.31% 27.65% 25.59% 34.85% 38.11% 44.79% 48.78% 52.37%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
76.06% 74.80% 73.12% 71.61% 69.77% 67.62% 65.05% 61.79% 55.08% 51.09% 47.49%
Debt to EBITDA
-0.60 -0.62 -0.63 -0.64 -0.65 -0.64 -0.65 -0.66 0.00 0.00 0.00
Net Debt to EBITDA
1.52 1.39 1.31 1.21 1.12 0.90 0.83 0.71 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.57 -0.53 -0.63 -0.64 -0.59 -0.51 -0.65 -0.66 0.00 0.00 0.00
Debt to NOPAT
-0.86 -0.89 -0.90 -0.91 -0.92 -0.92 -0.93 -0.93 0.00 0.00 0.00
Net Debt to NOPAT
2.18 1.98 1.87 1.74 1.60 1.28 1.19 0.99 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.81 -0.76 -0.89 -0.91 -0.84 -0.73 -0.93 -0.93 0.00 0.00 0.00
Altman Z-Score
2.67 1.41 -0.46 -0.08 -0.86 -1.22 -2.85 -3.56 -5.43 -5.77 -5.92
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
6.50 6.95 8.97 7.70 5.58 4.97 5.35 4.86 4.91 4.32 4.05
Quick Ratio
5.58 5.95 7.71 6.53 4.69 4.12 4.46 3.95 3.83 3.34 3.12
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-9.54 -12 -11 -10 -6.81 -9.03 -8.50 -7.30 -4.41 -5.24 -3.96
Operating Cash Flow to CapEx
-4,224.50% -2,615.30% -1,230.28% -1,740.87% -6,063.06% -4,392.69% -7,975.51% -9,170.79% -112,188.89% -521,400.00% -39,787.50%
Free Cash Flow to Firm to Interest Expense
-10.55 -13.31 -12.80 -11.24 -8.09 -11.56 -10.64 -9.07 -4.52 -4.31 -3.21
Operating Cash Flow to Interest Expense
-9.35 -13.36 -6.48 -8.13 -7.99 -16.93 -4.89 -10.14 -10.35 -4.28 -2.58
Operating Cash Flow Less CapEx to Interest Expense
-9.57 -13.87 -7.00 -8.59 -8.12 -17.32 -4.95 -10.25 -10.35 -4.28 -2.59
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.37 0.40 0.42 0.45 0.49 0.55 0.57 0.60 0.00 0.00 0.00
Accounts Receivable Turnover
6.61 7.81 7.65 7.29 6.64 7.14 6.71 7.20 0.00 0.00 0.00
Inventory Turnover
1.15 1.14 1.21 1.24 1.29 1.36 1.47 1.47 0.00 0.00 0.00
Fixed Asset Turnover
15.75 16.76 21.73 22.50 24.16 24.84 32.99 33.79 0.00 0.00 0.00
Accounts Payable Turnover
11.01 6.24 7.11 5.28 8.18 6.27 5.01 4.45 0.00 0.00 0.00
Days Sales Outstanding (DSO)
55.23 46.74 47.71 50.08 54.94 51.11 54.38 50.70 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
318.78 319.36 301.10 294.71 281.93 267.66 248.12 247.60 0.00 0.00 0.00
Days Payable Outstanding (DPO)
33.14 58.54 51.31 69.16 44.59 58.23 72.87 81.99 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
340.87 307.56 297.50 275.63 292.27 260.53 229.62 216.32 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
24 27 24 23 21 26 22 20 21 21 19
Invested Capital Turnover
2.87 2.78 3.28 3.44 3.72 3.30 4.00 4.22 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.21 1.58 0.47 0.13 -2.58 -1.17 -1.86 -2.77 -4.66 -1.10 -1.29
Enterprise Value (EV)
394 272 168 254 204 216 57 26 29 36 67
Market Capitalization
488 355 246 325 268 268 104 66 53 55 82
Book Value per Share
$3.09 $2.86 $2.61 $2.40 $2.17 $1.95 $1.72 $1.47 $1.09 $0.93 $0.80
Tangible Book Value per Share
$3.03 $2.80 $2.55 $2.34 $2.11 $1.89 $1.66 $1.42 $1.04 $0.87 $0.74
Total Capital
156 148 138 131 123 115 106 97 83 77 72
Total Debt
37 37 37 37 37 37 37 37 37 38 38
Total Long-Term Debt
35 32 37 37 34 29 37 37 37 37 38
Net Debt
-94 -83 -78 -71 -65 -52 -47 -40 -25 -19 -15
Capital Expenditures (CapEx)
0.20 0.45 0.47 0.42 0.11 0.30 0.05 0.09 0.01 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
12 16 15 15 13 18 13 12 12 12 10
Debt-free Net Working Capital (DFNWC)
129 132 130 123 115 107 98 88 74 68 63
Net Working Capital (NWC)
127 127 130 123 112 99 98 88 74 68 63
Net Nonoperating Expense (NNE)
4.14 3.57 4.39 4.25 3.78 4.25 4.81 3.88 4.58 3.74 3.15
Net Nonoperating Obligations (NNO)
-94 -83 -78 -71 -65 -52 -47 -40 -25 -19 -15
Total Depreciation and Amortization (D&A)
-0.03 0.05 -0.06 -0.02 -0.04 0.08 0.18 0.22 0.27 0.35 0.34
Debt-free, Cash-free Net Working Capital to Revenue
17.59% 21.24% 19.78% 18.53% 15.81% 20.39% 14.57% 12.71% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
188.45% 180.66% 169.69% 154.76% 137.23% 122.09% 107.87% 96.51% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
185.31% 173.50% 169.57% 154.64% 133.44% 113.17% 107.76% 96.39% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.36) ($0.36) ($0.39) ($0.36) ($0.33) ($0.36) ($0.38) ($0.34) ($0.33) ($0.24) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding
37.97M 38.64M 38.94M 39.28M 39.11M 39.95M 40.43M 40.94M 41.90M 42.47M 43.18M
Adjusted Diluted Earnings per Share
($0.36) ($0.36) ($0.39) ($0.36) ($0.33) ($0.36) ($0.38) ($0.34) ($0.33) ($0.24) ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding
37.97M 38.64M 38.94M 39.28M 39.11M 39.95M 40.43M 40.94M 41.90M 42.47M 43.18M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
38.54M 38.82M 39.15M 39.49M 39.80M 40.26M 40.75M 41.25M 42.24M 42.95M 43.55M
Normalized Net Operating Profit after Tax (NOPAT)
-9.74 -10 -11 -9.89 -9.39 -10 -10 -10 -9.07 -6.34 -5.24
Normalized NOPAT Margin
-50.54% -53.97% -52.62% -48.51% -39.52% -45.23% -43.43% -46.86% -44.06% -27.86% -22.96%
Pre Tax Income Margin
-70.75% -71.94% -73.34% -68.44% -55.28% -63.51% -62.85% -64.31% -65.60% -43.71% -36.10%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-15.79 -15.99 -17.57 -16.08 -15.84 -18.43 -18.67 -16.94 -13.20 -7.44 -5.96
NOPAT to Interest Expense
-10.78 -11.52 -12.27 -11.10 -11.15 -13.05 -12.97 -12.52 -9.29 -5.21 -4.25
EBIT Less CapEx to Interest Expense
-16.01 -16.50 -18.10 -16.55 -15.98 -18.82 -18.73 -17.05 -13.20 -7.44 -5.97
NOPAT Less CapEx to Interest Expense
-11.00 -12.03 -12.80 -11.57 -11.29 -13.44 -13.03 -12.63 -9.30 -5.21 -4.26
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Pulmonx’s Q2 2026 results show improving operating efficiency, but the company remains unprofitable and continues to consume cash. Revenue increased to $22.8 million from $20.6 million in Q1 2026, although it was down approximately 4.6% from $23.9 million in Q2 2025. The longer-term trend is more favorable, with quarterly revenue rising from $14.5 million in Q1 2023 to $22.8 million in Q2 2026.

  • Gross margin improved materially. Q2 2026 gross profit was $17.7 million, representing a gross margin of approximately 78%, compared with roughly 72% in Q2 2025. This indicates better product economics despite the year-over-year revenue decline.
  • Operating losses narrowed. The operating loss improved to $9.1 million in Q2 2026 from $13.0 million in Q1 2026 and $14.8 million in Q2 2025. Total operating expenses also fell to $26.8 million from $29.0 million sequentially and $32.0 million a year earlier.
  • Net losses are trending in the right direction. Pulmonx reported a net loss of $10.1 million, or $0.24 per share, compared with a $13.7 million loss, or $0.33 per share, in Q1 2026 and a $15.2 million loss, or $0.38 per share, in Q2 2025.
  • Operating cash burn improved sequentially. Cash used in operating activities declined to $5.2 million in Q2 2026 from $10.1 million in Q1. The improvement reflects the smaller net loss and a favorable $258,000 contribution from operating assets and liabilities.
  • Liquidity remains substantial. Pulmonx had $55.8 million of cash and equivalents plus $259,000 of restricted cash at June 30, 2026. Against approximately $37.5 million of total debt, the company held an estimated $18.3 million net cash position.
  • Near-term balance-sheet coverage is strong. Current assets of $88.1 million were more than four times current liabilities of $20.4 million. This provides meaningful flexibility to fund operations and commercial development in the near term.
  • Financing activity has become more important to liquidity. In Q1 2026, Pulmonx issued $38.8 million of debt while repaying $37.0 million, producing only modest net financing proceeds. Q2 included another $513,000 of debt repayment, suggesting that recent liquidity has not been generated by operations alone.
  • Pulmonx has not yet demonstrated a path to profitability. The company has reported recurring quarterly net losses throughout the periods provided, with retained earnings reaching a deficit of $545.3 million by Q2 2026.
  • Cash reserves have steadily declined over the longer term. Cash and equivalents fell from approximately $110.4 million in Q1 2023 to $55.8 million in Q2 2026. Although the latest quarterly burn rate improved, continued operating losses could materially reduce this cushion.
  • Share dilution is a continuing consideration. Weighted-average basic shares increased from 37.6 million in Q1 2023 to 42.5 million in Q2 2026, an increase of roughly 13%. Additional equity financing could further dilute existing shareholders if cash burn persists.

Overall, the financial trend is mixed but improving operationally. Revenue has grown over the multi-year period, gross margins have strengthened, and both operating losses and cash burn narrowed in Q2 2026. However, Pulmonx remains dependent on its cash balance and financing capacity while it works toward sustainable profitability.

11/17/26 11:53 PM ETAI Generated. May Contain Errors.

Pulmonx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pulmonx's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Pulmonx's net income appears to be on a downward trend, with a most recent value of -$56.39 million in 2024, falling from -$18.48 million in 2018. The previous period was -$60.84 million in 2023. See where experts think Pulmonx is headed by visiting Pulmonx's forecast page.

Pulmonx's total operating income in 2024 was -$57.70 million, based on the following breakdown:
  • Total Gross Profit: $62.00 million
  • Total Operating Expenses: $119.71 million

Over the last 6 years, Pulmonx's total revenue changed from $20.00 million in 2018 to $83.79 million in 2024, a change of 318.9%.

In the past 13 quarters, Pulmonx's cash and equivalents has ranged from $52.69 million in Q3 2026 to $101.58 million in Q2 2023, and is currently $52.69 million as of their latest financial filing in Q3 2026.

Pulmonx had total debt of $37.18 million at the end of 2024, a 0.2% decrease from 2023, and none in 2018.

Over the last 6 years, Pulmonx's book value per share changed from 0.00 in 2018 to 2.17 in 2024, a change of 217.3%.



Financial statements for NASDAQ:LUNG last updated on 11/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners